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P27A is a novel synthetic malaria vaccine candidate derived from the blood stage
Plasmodium falciparum protein Trophozoite Exported Protein 1 (TEX1/PFF0165c). In
phase 1a/1b clinical trials in malaria unexposed adults in Switzerland and in malaria
pre-exposed adults in Tanzania, P27A formulated with Alhydrogel and GLA-SE adjuvants
induced antigen-specific antibodies and T-cell activity. The GLA-SE adjuvant induced
significantly stronger humoral responses than the Alhydrogel adjuvant. Groups of
pre-exposed and unexposed subjects received identical vaccine formulations, which
supported the comparison of the cellular and humoral response to P27A in terms of
fine specificity and affinity for populations and adjuvants. Globally, fine specificity of the
T and B cell responses exhibited preferred recognized sequences and did not highlight
major differences between adjuvants or populations. Affinity of anti-P27A antibodies was
around 10−8 M in all groups. Pre-exposed volunteers presented anti-P27A with higher
affinity than unexposed volunteers. Increasing the dose of GLA-SE from 2.5 to 5µg
in pre-exposed volunteers improved anti-P27A affinity and decreased the number of
recognized epitopes. These results indicate a higher maturation of the humoral response
in pre-exposed volunteers, particularly when immunized with P27A formulated with
5µg GLA-SE.
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INTRODUCTION
In 2018, malaria affected 213 million people and caused 405,000 deaths worldwide. Sub-Saharan
Africa accounts for nearly 93.4% of total malaria cases. Children under 5 years of age are most
susceptible to malaria and account for 67% of all malaria deaths (1). Plasmodium falciparum (Pf )
causes the most serious forms of malaria. Though there are treatments and promising vaccine
candidates for this disease, a highly efficacious vaccine is not currently available (2, 3). Sequencing
of the Pf genome provided over 5,300 potential gene and protein targets for drug and vaccine
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development (4). Using a genome-wide approach, new protein
fragments have been identified with defined structural features
that are potential targets for antibodies that inhibit parasite
growth (5). One of these fragments, P27A, consists of 104 amino
acid residues (aa) and is part of Pf Trophozoite Exported Protein
1, TEX1/PFF0165c (5–7). This novel fragment is particularly
interesting because its sequence is highly conserved with a single
mutation E/G at position 292 (5, 7). The P27A amino acid
sequence indicates that the fragment assumes an intrinsically
unstructured conformation, which was further established by
circular dichroism studies (5). Unstructured antigens/fragments
that consist of over 50 amino acid residues and exhibit biological
activity were first reported by Wright and Dyson (8), followed by
reports of other fragments specifically relevant to the plasmodia
parasite and other organisms by Feng et al. and Corradin et al. (9–
11). Purified human antibodies with P27A-specific affinity inhibit
parasite activity in vitro, and the anti-P27A response is associated
with protection (5, 7). Peptide vaccines induce a direct, strong
immune response, and are cost-effective and easy to produce and
store (12–14). Due to the promising properties of P27A as an
anti-malaria vaccine candidate, phase 1a and 1b clinical trials
were performed in malaria unexposed subjects from Switzerland
(CH) and in malaria pre-exposed healthy adults from Tanzania
(TZ) to evaluate its safety and immunogenic properties in
combination with adjuvants Alhydrogel or glucopyranosyl lipid
A in a stable emulsion (GLA-SE) (15). The vaccine was safe and
induced a strong humoral response, particularly in combination
with GLA-SE, andwas active in inhibiting in vitro parasite growth
(15). In this report, we characterized the anti-P27A cellular and
humoral responses generated in vaccinated subjects, particularly
the fine specificity and IgG affinities. Groups of pre-exposed
and unexposed subjects received identical vaccine formulations,
which supported comparisons of populations and adjuvants.
MATERIALS AND METHODS
Peptides for in vitro Use
Ten 20-mer synthetic peptide fragments overlapping on 10
amino acids (P1–P10) were synthesized using the solid-phase
Fmoc strategy (Table 1) (6, 12). Peptides were purified by reverse-
phase high-pressure liquid chromatography and analyzed by
mass spectrometry (6). P27A GLP and GMP preparations
(Almac, Craigavon, UK) were used throughout the study. For cell
stimulation, lyophilized peptides were resuspended in apyrogenic
sterile water and filtered through a 0.22µm filter.
Human Samples
P27A formulated in Alum or in GLA-SE was studied in parallel
in a phase 1a clinical trial in Lausanne, Switzerland (CH) and
in a 1b clinical trial in Bagamoyo, Tanzania (TZ) (15). Trials
were registered in clinicaltrials.gov (NCT01949909) and www.
pactr.org (PACTR201310000683408). As described in Figure S1,
two groups from CH and three groups from TZ, each consisting
of eight healthy individuals, received three intramuscular (i.m.)
injections at days 0, 28, and 56. Volunteers of groups CH-
Alum/50 and TZ-Alum/50 received 50µg P27A and 0.85mg
Alhydrogel adjuvant, per injection. In groups CH-GLA2.5/50,
TABLE 1 | Sequences of P27A and overlapping 20-mers peptides.
Peptide PFF0165c Sequence
P27A-LSP 223–326 HNNNEKNISY//QEEKENMLNNKKRS
P1 223–242 HNNNEKNISYDKNLVKQEND
P2 233–252 DKNLVKQENDNKDEARGNDN
P3 243–262 NKDEARGNDNMCGNYDIHNE
P4 253–272 MCGNYDIHNERGEMLDKGKS
P5 263–282 RGEMLDKGKSYSGDEKINTS
P6 273–292 YSGDEKINTSDNAKSCSGDE
P7 283–312 DNAKSCSGDEKVITSDNGKS
P8 293–322 KVITSDNGKSYDYVKNESEE
P9 303–322 YDYVKNESEEQEEKENMLNN
P10 313–332 QEEKENMLNNKKRSLECNPN
Underlined amino acids in P10 are not present in P27A-LSP sequence.
TZ-GLA2.5/50, and TZ-GLA5/50, they received 50µg P27A
and 2.5µg or 5µg GLA-SE. Sera, plasma and peripheral blood
mononuclear cells (PBMC) were taken at day 0 (D0, pre-
vaccination) and at day 84 (D84, 1 month after the third
injection) using the same procedure at both sites. PBMC were
separated from blood on a density gradient (Ficoll-Paque Plus)
and were stored in liquid nitrogen until use. Positive controls
were a pool of sera from eight exposed subjects from Burkina
Faso, set arbitrarily to 152AU/mL to P27A, and the plasma
of a vaccinated volunteer with a high response (5,420AU/mL
to P27A). Negative control sera were pooled from 20 non-
exposed individuals.
ELISPOT Determination
After thawing, PBMC were plated in 96-round-bottom well
plates at 2.5 × 105 cells/well in 8% human AB serum in
RPMI. Cells were stimulated separately in triplicates with
each of the following: 50µg/mL of P27A, 10µg/mL of each
20-mer P27A peptide, a pool of the ten 20-mer peptides
(10µg/mL of each), 5µg/mL of phytohaemagglutinin (PHA)
and unstimulated as controls. For the stimulation with PHA,
40,000 to 75,000 cells were plated. After 20–24 h of culturing
at 37◦C 5% CO2, cells were transferred for a 15–20 h
supplementary culturing on a nitrocellulose-lined microtiter
plate coated with 100µL of capture anti-hu IFN-γ (5µg/mL)
and blocked (BDTM Human IFN-gamma ELISPOT Set). At
the end of culture, the plate was washed and incubated for
2 h at room temperature (RT) with 100µL/well of biotinylated
anti-hu IFN-γ antibody (2µg/mL, BD). After washing, plate
was incubated with 100 µL/well of streptavidin-HRP conjugate
(BD) for 1 h at RT. After washing, 100µL/well of 3-amino-9-
ethyl-carbazole (AEC, BDTM AEC substrate reagent set) was
added for a 5–30min incubation stopped with tap water.
After plate drying, spots were counted using a computer
assisted video image analyzer (EliSpot Robotic Systems with
AID EliSpot Software Version 6.x, ELROBO6i, AID, D-
Straßberg). Results were expressed as spot forming units
(SFU)/million PBMC.
Frontiers in Immunology | www.frontiersin.org 2 March 2020 | Volume 11 | Article 412
Geiger et al. Malaria Vaccine P27A
Humoral Response
The immunoglobulin G (IgG) immune response against the
synthetic P27A and overlapping 20-mers was measured using
an enzyme-linked immunosorbent assay (ELISA) (5, 15).
Microtiter plates (NuncTM Maxisorp, Denmark) were coated at
a concentration of 2 and 5µg/mL, respectively, at RT for 1 h then
blocked with PBS-3% milk for 1 h. Samples and controls were
serially diluted in PBS-1.5% milk-0-05% Tween and added at
50µL per well. Controls were present on each ELISA plate. Anti-
hu IgG secondary antibodies conjugated to alkaline phosphatase
(A-9544, Sigma, St. Louis, MO), diluted 1:1000 in PBS-1.5%
milk-0-05% Tween, were added to each well. p-Nitrophenyl
phosphate substrate tablets (SigmafastTM, Sigma, St. Louis, MO)
were dissolved and added to each well. The optical density (OD)
of each well was measured at 405 nm using an OpsysMR plate
reader (Dynex Technologies). Results were expressed as AU/mL
based on the standard curve obtained from the response of the
positive control pool of sera to P27A.
ELISA-Based Determination of Apparent
Affinity (EC50) and Avidity
EC50 represents the concentration of soluble peptide inhibitor
required to obtain 50% inhibition of IgG binding to coated
peptide (16). The competitive ELISA protocol (17–19) was
adapted and modified. 96-well microtiter plates (NuncTM
Maxisorp, Denmark) were coated with 50µL of 2µg/mL of
P27A at RT for 1 h then blocked with PBS-3% milk for 1 h.
Sera samples, at the dilution giving 50% of the maximal binding
to coated P27A, were incubated 30min at RT with 1:10 serial
dilutions of competitor soluble P27A or 20-mer peptides starting
with concentrations of either 200µg/mL or 105 M and without
peptide as control (max). Then, 50µL of each well was plated
in duplicates onto the P27A coated plate, incubated at RT for
2 h and developed as described above. Percentage of inhibition
was calculated as: 100-(ODi–ODmin)/(ODmax–ODmin) × 100,
ODmin representing signal in well without serum. EC50 and
EC10 were calculated using the linear function: % inhibition =
f [log (peptide concentration)]. Using the same method as for
affinity, avidity was evaluated using 1:2 serial dilutions of the
chaotropic reagent guanidine hydrochloride (GuHCl, from 6M to
0.1M) as inhibitor and without GuHCl as control (max). Avidity
was expressed as the concentration of GuHCl (M) required to
obtain 50% inhibition of IgG binding to coated P27A.
Affinity Purified Human Antibodies
P27A-sepharose conjugate was prepared with 16mg of P27A
mixed with 2.5 g of CNBr-Sepharose 4B (Amersham Bioscience
AB, S-Uppsala) according to the manufacturer’s protocol. Five to
7mL of D84 plasma diluted 1:5 in PBS 0.5M NaCl was mixed
with the P27A-sepharose conjugate and stirred gently overnight
at 4◦C. After centrifugation, washing and transferring the beads
into a syringe, bound antibodies were eluted with glycine (0.1M,
pH 2.5). The collected fractions were instantly neutralized
with PBS (10x, pH 7.4), and their protein concentration
was determined by the absorbance at 280 nm and anti-P27A
IgG by ELISA. Fractions of interest were pooled. Total IgG
from D0 plasma were purified by affinity chromatography on
protein G using the manufacturer’s protocol (GammaBindTM
Plus SepharoseTM, GE Healthcare, S-Uppsala).
Surface Plasmon Resonance
Measurements of Avidity in Human Sera
A Biacore 8K instrument (GE Healthcare, Glattbrugg,
Switzerland) was used to determine the apparent dissociation
constant (KD) of antigen-specific human polyclonal antibodies
to P27A. Around 10µg/mL of P27A in 10mM sodium acetate,
pH = 4.5 was immobilized on a CM5 chip to reach the final
chip density of about 150 response units (RU). Affinity-purified
antibodies from volunteers were 1:2 serially diluted from 1µM
down to 200 pM and injected at a flow rate of 10µL/min.
After each cycle of injection, the surface chip was regenerated
by flushing it with 3M MgCl for two consecutive 30-second
intervals. Association (kon), dissociation (koff) and equilibrium
(KD) constants were determined using 1:1 Langmuir binding
kinetic fits provided by the suite of analysis software from
Biacore 8K (GE Healthcare #29310604).
Statistical Analysis
The data were analyzed using GraphPad Prism 7.03. Wilcoxon
and Mann Whitney non-parametric tests were performed
to compare intra- and inter- group values, respectively.
Spearman and Pearson correlations between parameters were
also performed. A two-way ANOVA test was used to compare
antibody titers of each adjuvant group against each peptide. The
significance level used for each test was α = 0.05.
RESULTS
T-Cell Response and Fine-Specificity
The effect of adjuvants on the T-cell response was evaluated
in unexposed volunteers. The IFN-γ response to each 20-mer
peptide, individual or pooled, or to the full length P27A (P27A-
LSP) was determined by ELISPOT at D0 and D84 (Figure 1).
Volunteers from the groups CH-Alum/50 and CH-GLA2.5/50
exhibited a significant IFN-γ response to the pool of 20-mer
peptides and P27A-LSP. The two adjuvant groups of unexposed
volunteers had similar IFN-γ responses. The average response
to the pool of 20-mer peptides was 27.35 [0; 200] SFU/million
PBMC for the CH-Alum/50 group and 20 [0; 106.7] SFU/million
PBMC for the CH-GLA2.5/50 group; Wilcoxon p-values were
0.0156 and 0.0313, respectively. The average response to P27A-
LSP was 28 [0; 256] SFU/million PBMC for the CH-Alum/50
group and 16.65 [0; 120.4] SFU/million PBMC for the CH-
GLA2.5/50 group; Wilcoxon p-values were 0.0156 and 0.0156,
respectively. By comparison, the IFN-γ responses to individual
20-mer peptides was weaker, but the sum of the individual
responses was about equal to that of the 20-mer peptide pool and
P27A-LSP. No comparative difference in intensity was observed
between the adjuvant groups. The distribution of the IFN-γ
responses along the sequence varies widely between volunteers
(Figure 2A). However, the resulting responses per group focused
on 4–5 peptides, principally P1, P2, P5, and P8 with Alum and on
P1 and P8 with GLA-SE (Figure 2B).
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FIGURE 1 | Cellular responses to P27A and overlapping 20-mers at D84 in Phase 1a. PBMC from unexposed volunteers (CH-Alum/50 (n = 8) and CH-GLA2.5/50)
(n = 8) at D84 were stimulated with P27A-LSP or the overlapping 20-mer peptides P1 to P10, individually or as a pool. The frequency of IFN-γ secreting cells was
revealed by ELISPOT. Results are expressed as SFU/ million PBMC. Comparisons between groups were done using Mann-Whitney test; p-values are indicated.
Responses at D0 and D84 to P27A-LSP and the pool of peptides are shown with Wilcoxon test p-values.
Antibody Response and Fine-Specificity
The fine specificity of the humoral response was determined by
ELISA using individual 20-mer peptides. We previously reported
that GLA-SE formulation induced higher anti-P27A titers than
Alum, and that pre-exposed subjects exhibited lower humoral
responses as compared to unexposed subjects. Furthermore, an
increase in the dose of GLA-SE in the vaccine formulation was
associated with an increase in antibody titers (5, 15).We observed
that the antibody responses directed to the 20-mer peptides had
the same intensity profile as anti-P27A. To characterize the fine
specificity and compare responses between groups, we analyzed
the proportion of responses to the 20-mers peptides. Figure 3A
shows the percentage of recognition for each 20-mer peptide,
and Figure 3B indicates the proportions of the responses to each
peptide in the different groups. Comparisons among the two
adjuvants used and the volunteers at the two sites are shown
in Figure 3C. The most striking observations found are: (1)
similarity of low or no responses to peptides P2, P3, and P9 in
all groups (Figure 3A); (2) P10 is most frequently recognized
followed by P1 and P8; (3) comparison of the TZ-GLA-SE2.5/50
and TZ-GLA-SE5/50 pie graphs shows that an increase in GLA-
SE from 2.5 to 5µg induced a significant reduction in the
number of recognized peptides (p < 0.0001 in Kruskal Wallis,
Figures 3B,C); and (4) globally, both formulations induced a
similar pattern of humoral responses in the two populations,
except to peptides P5 and P7. Recognition frequency of P5
was significantly lower in the pre-exposed group than in the
unexposed group (p= 0.0098), while on the contrary, recognition
frequency of P7 was significantly higher in the pre-exposed group
than in the unexposed group (p = 0.0092), regardless of the
adjuvant formulation (Figure 3C).
Antibody Affinities and Avidities to P27A
We performed a competitive ELISA to evaluate the functional
antibody affinity for soluble P27A of each volunteer after the
third vaccination (Day 84).We observed a 2-log difference within
individual EC50 (Figure 4). Figure 4A shows that the overall
affinity for soluble P27A was significantly higher in the pre-
exposed group than in the unexposed group (median EC50 of
1.26 × 10−8 and 2.19 × 10−8, respectively, p = 0.0395). In
Figure 4B, the two adjuvants induced anti-P27A responses with
similar EC50. Interestingly, increasing the dose of GLA-SE from
2.5 to 5µg induced responses with higher functional affinity in
the pre-exposed group (Figure 4C) in addition to higher titers.
Therefore, in this population, affinity correlated with IgG titers
(Figure 4D). This was not the case for unexposed subjects, for
which data is not shown. Finally, adjuvant effect on affinity to
20-mer peptides P1, P5, P8, and P10 was analyzed using phase
1a samples that were positive for these peptides. Peptides showed
low affinity compared to P27A LSP, with no difference between
adjuvants (Figure S2).
We also measured the adjuvant effect on IgG avidity to bound
P27A by ELISA using the chaotropic agent guanidinium
hydrochloride. Representative serum samples from the
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FIGURE 2 | Repartition of the cellular recognition along the sequence of P27A at D84 in Phase 1a. PBMC from unexposed volunteers [CH-Alum/50 (n = 8) and
CH-GLA2.5/50 (n = 8)] at D84 were individually stimulated with overlapping 20-mer peptides P1 to P10, and the frequency of IFN-γ secreting cells revealed by
ELISPOT. (A) Heat map indicates the individual responses to each 20-mer peptide,Y-axis represents the volunteer ID and the X-axis represents the frequency of IFN-γ
secreting cells as SFU/million PBMC, and individual pies illustrate the repartition of responses to the 20-mers as % of the total response. (B) Pie graphs show the
median value per vaccination group of the percentage of IFN-γ secreting cells to each 20-mer peptide.
unexposed population were evaluated. IgG avidity for plastic
bound P27A was significantly higher in the CH-Alum/50 group
than in the CH-GLA2.5/50 group (Figure 4E). Additionally, we
used SPR to measure the binding kinetics of eight representative
affinity purified sera samples with the highest anti-P27A titer
from groups CH-Alum/50, CH-GLA2.5/50, and TZ-GLA2.5/50
at D84. Binding kinetics were clearly concentration-dependent
for all the tested individuals (Figure S3). The avidities to bound
P27A showed KD values within the nanomolar range in the three
groups, with a tendency for a lower avidity in those vaccinated
with GLA-SE (Figure 4F). This aligns with the results obtained
by ELISA using a chaotropic agent (Figure 4E).
DISCUSSION
P27A formulated with Alhydrogel and GLA-SE tested in phase
1a and 1b clinical trials conducted in Switzerland and Tanzania
demonstrated promising T and B cell responses. The GLA-SE
formulation, showed the most promise, with the observation that
the intensity of response to identical vaccine formulations was
lower for pre-exposed volunteers than for unexposed volunteers
(15). In this follow-up report, we intended to characterize the
fine T and B cell responses directed to the antigen, focusing
on the potential impact of adjuvants and the exposure status of
volunteers to P. falciparum.
Given the unstructured nature of P27A, the defined fine
specificity of cellular and humoral response was easily assessed
by using overlapping 20-mer peptides covering the entire P27A
sequence as previously shown for MSP2 family specific and
constant regions (20). As measured by ELISPOT, the T-cell
response specific to the ten 20-mer peptides was not particularly
elevated. However, P27A elicited a low but positive response in 12
of 16 volunteers. This was also evident in the concomitant B-cell
response found in all volunteers, without qualitative difference
between formulations.
Examining the antigen specificity with the 20-mer peptides
indicates that the entire P27A sequence is a target of
the humoral response in both cohorts, with no statistical
difference between unexposed and pre-exposed volunteers
except for peptides five and seven. It is not clear whether
the difference observed is due to the difference in genetic
background or to pre-exposure to malaria. Of note, the
most recognized 20-mer peptides are peptide fragments 1,
5, 8, and 10, where 1 and 10 cover the N- and C-
termini of P27A. The N- and C- termini are generally more
flexible than the interior segment and may therefore have a
higher probability of adapting favorably to different antibody
binding sites.
Direct ELISA to plastic-bound antigens and the concomitant
inhibition of the response by soluble P27A and its 20-mer
peptides determine the antigen specificity and the apparent
KD of the interaction between the single antigens and
antibodies. Competitive ELISA results show that the apparent
KD for the interaction between antigen and antibodies is
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FIGURE 3 | Repartition of the fine specificity of the humoral response along the sequence of P27A at D84 in Phase 1a and 1b. The fine specificity of the humoral
response was determined by ELISA using sera from unexposed volunteers (CH-Alum/50 and CH-GLA2.5/50) and exposed volunteers (TZ-Alum/50, TZ-GLA2.5/50,
and TZ-GLA5/50) against individual 20-mer peptides. (A) Heat map indicates the individual repartition of antibody responses to each 20-mer peptide, P1 to P10, over
the sum of the responses, for each vaccination group. Right Y-axis represents the volunteer ID and the left Y-axis denotes the percentage value. (B) Pie graphs show
the median proportion of humoral response to each 20-mer peptide for each vaccination group. (C) Pie graphs represent the median repartition of humoral responses
of all volunteers grouped either by adjuvant type (Alum or GLA-SE) or by site (CH or TZ). Comparisons per peptide were done using Mann-Whitney test; *p < 0.05;
**p < 0.01; ***p<0.001.
around 10−8 M in vaccinated subjects. Nevertheless, pre-
exposed volunteers exhibit significantly higher affinity,
probably indicating a higher immune maturation due
to the boost from the three injections of the vaccine in
addition to the natural immunity induced by previous
malaria exposure.
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FIGURE 4 | Relative affinity and avidity of specific IgG to P27A at Day 84 in Phase 1a and 1b. Strength of the binding of specific IgG to P27A was evaluated at day 84
for all volunteers (CH and TZ) by competition ELISA using soluble P27A as competitor (A–C) or guanidium chloride GuHCl (E). Results are expressed as EC50.
(A) Comparison of relative antibody affinity for P27A in pre-exposed and unexposed subjects, from TZ (3 groups, n = 23) and CH (2 groups, n = 16), respectively.
(B) Comparison of relative antibody affinity for P27A in each adjuvant group, Alum (n = 16) and GLA-SE (n = 23). (C) Comparison of relative antibody affinity for P27A
in each TZ-GLA-SE dose group, 2.5 or 5 ug. (D) Correlation between anti-P27A IgG titer (log AU/mL) and affinity (log M) in pre-exposed TZ subjects, n = 23. Pearson
r and p-values are indicated. (E) Comparison of antibody avidity for P27A in unexposed volunteers grouped by adjuvant type, Alum (n = 5) and GLA-SE (n = 5).
(F) Antibody avidity for P27A in eight samples from TZ-GLA2.5/50 (n = 3, blue circles), CH-GLA2.5/50 (n = 3, blue triangles), and CH-Alum/50 (n = 2, yellow
triangles). Antibody avidity was determined by SPR with kinetic constants Kon (association) and Koff (dissociation) and equilibrium KD = Koff/Kon. (A–C,E) Lines indicate
medians and quartiles, p-values of Mann-Whitney tests are indicated. TZ subjects, circles; CH subjects, triangles; Alum, yellow symbols; GLA-SE, blue symbols.
Moreover, increasing the dose of GLA-SE in the formulation
favored higher anti-P27A titers (15), higher affinity and a
reduction of the number of epitopes recognized. These are
signs of an efficient humoral maturation, and corroborate the
observation reported by Hill et al. (21) regarding the repertoire
of Tfh and antibody secreting cells (ASC) of the volunteers from
group TZ-GLA-SE5/50. Hill et al. observed that the high anti-
P27A responses induced by GLA-SE are correlated with high
oligoclonal expansion of extrafollicular ASC and Tfh expressing
specific TCR (21).
Interestingly, the Alum formulation seems to induce an anti-
P27A response with higher avidity than the GLA-SE formulation,
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particularly by ELISA. This discrepancy may be due to a
technical bias. The avidity ELISA assay using a chaotropic
agent measures the strength of Ig binding to plastic-bound
peptides, while the affinity inhibition ELISA assay measures
the strength of Ig binding to a soluble peptide in a native
conformation. Because P27A is intrinsically unstructured and
therefore flexible, its conformation is probably more prone
to alteration when adsorbed to the plastic surface of the
ELISA plate. The vaccine formulated in Alum, in which the
P27A is absorbed on aluminum salt surfaces, vaccine may
possibly induce responses to altered bound-peptides, at least
partially. On the contrary, P27A in the GLA-SE emulsion
will favor antibodies preferably or exclusively directed to and
with high affinity to the soluble native P27A, so bound
P27A is recognized with less affinity, and therefore with
less avidity.
Moreover, while the adjuvants influence the magnitude of
the immune response, studies have observed that they have less
influence on the fine specificity and affinity of antigen-specific
antibodies (22). The dose of adjuvant was making an exception
to this, since we observed that a significant increase in affinity
correlated with increased titers and the dose of GLA-SE in pre-
exposed volunteers.
In conclusion, the two P27A vaccine formulations using
two different adjuvants, Alhydrogel and GLA-SE, largely exhibit
similar characteristics at the T and B cell level, independent
of the intensity of the responses induced. Genetic differences
between the Swiss and Tanzanian cohorts and previous exposure
to the malaria parasite are likely to shape the subsequent
immune response to antigen vaccination, which may explain
observed differences in humoral responses between the two
populations. The formulation of P27A in 5µg GLA-SE is
likely to induce an efficient immune response in pre-exposed
populations, the target population that could benefit from the
vaccine. This formulation may also be suitable for unexposed
travelers since recent trials showed that 2 or 5µg GLA-SE
vaccine formulations were similarly safe (23, 24). Further studies
to formally confirm these observations should be performed
in phase 2a and 2b clinical trials covering a greater number
of volunteers.
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